BRIEF published on 03/27/2025 at 19:17, 3 months 18 days ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
BRIEF published on 03/27/2025 at 19:17, 3 months 18 days ago Advicenne annonce une croissance solide et des projets futurs pour 2025 Amélioration Des Flux De Trésorerie Perspectives 2025 Résultats Financiers D'Advicenne Croissance Des Ventes De Sibnayal Progrès Réglementaires ADV7103
PRESS RELEASE published on 03/27/2025 at 19:12, 3 months 18 days ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
PRESS RELEASE published on 03/27/2025 at 19:12, 3 months 18 days ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne annonce ses résultats annuels 2024 avec un chiffre d'affaires en hausse de 9,4% grâce à Sibnayal® en Europe; avancées réglementaires majeures aux Etats-Unis Chiffre D'affaires Résultats Annuels États-Unis Advicenne Sibnayal
BRIEF published on 10/01/2024 at 07:05, 9 months 14 days ago Advicenne progresse aux États-Unis avec des avis positifs de la FDA sur ADV7103 FDA Advicenne ADV7103 ATRd Cystinurie
BRIEF published on 10/01/2024 at 07:05, 9 months 14 days ago Advicenne Advances in US with Positive FDA Reviews for ADV7103 FDA ADV7103 ATRd Advicenna Cystinuria
PRESS RELEASE published on 10/01/2024 at 07:00, 9 months 14 days ago Informations privilégiées / Autres communiqués Advicenne franchit des étapes majeures aux Etats-Unis pour ADV7103 avec des avis favorables de la FDA, ouvrant des opportunités partenariales, simplifiant les démarches réglementaires et cliniques FDA Développement États-Unis Partenaires Advicenne
PRESS RELEASE published on 10/01/2024 at 07:00, 9 months 14 days ago Inside Information / Other news releases Advicenne achieves major milestones in the US with positive FDA opinions on ADV7103, accelerating partnership outlook for commercialization, preparing for clinical development in cystinuria, and seeking commercial partners Commercialization Advicenne ADV7103 Cystinuria FDA Opinions
BRIEF published on 05/15/2024 at 09:07, 1 year 2 months ago Advicenne Shareholders Approve Board-Supported Resolutions at General Meeting Euronext Growth Paris Pharmaceutical Industry General Meeting Advicenne Rare Renal Diseases
BRIEF published on 05/15/2024 at 09:07, 1 year 2 months ago Les actionnaires d'Advicenne approuvent les résolutions soutenues par le conseil d'administration lors de l'assemblée générale Assemblée Générale Euronext Croissance Paris Industrie Pharmaceutique Conseille Maladies Rénales Rares
Published on 07/15/2025 at 09:05, 2 hours 43 minutes ago Nano One Selected to Join U.S. ALTA and Strengthen North American Battery Supply Chain
Published on 07/15/2025 at 09:01, 2 hours 47 minutes ago Star Copper Provides Site Visit Update of Ongoing Drill Campaign in British Columbia's Golden Triangle
Published on 07/15/2025 at 07:10, 4 hours 38 minutes ago SAINT BELLA Debuts in the U.S., Setting a New Standard for Postpartum Care
Published on 07/15/2025 at 03:00, 8 hours 48 minutes ago Forte Group Announces Initiatives to Strengthen Financial Position
Published on 07/15/2025 at 02:30, 9 hours 18 minutes ago GECC Reports Fiscal 2025 Q3 Financial Results
Published on 07/15/2025 at 10:39, 1 hour 8 minutes ago CPI Property Group announces the invitation to holders of its outstanding Senior Unsecured Green Notes due 7 May 2029 to tender the Notes for purchase by the Company for cash
Published on 07/15/2025 at 10:00, 1 hour 47 minutes ago Original-Research: Samara Asset Group PLC (von GBC AG): BUY
Published on 07/15/2025 at 10:00, 1 hour 48 minutes ago Mallia Innovations appoints five leading international experts in hair science to its Scientific Advisory Board
Published on 07/15/2025 at 09:15, 2 hours 33 minutes ago thyssenkrupp nucera Continues Stable Business Development in the Third Quarter and Specifies Outlook for 2024/2025
Published on 07/15/2025 at 07:00, 4 hours 48 minutes ago Biophytis s’associe à Lynx Analytics dans le domaine de l’IA pour accélérer la découverte de médicaments contre la sarcopénie
Published on 07/15/2025 at 07:00, 4 hours 48 minutes ago Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia
